These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 20484892

  • 1. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease.
    Siragy HM, Carey RM.
    Am J Nephrol; 2010; 31(6):541-50. PubMed ID: 20484892
    [Abstract] [Full Text] [Related]

  • 2. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
    Remuzzi G, Perico N, Macia M, Ruggenenti P.
    Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578
    [Abstract] [Full Text] [Related]

  • 3. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J, Aparicio LS, Waisman GD.
    Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
    [Abstract] [Full Text] [Related]

  • 4. Independent regulation of renin-angiotensin-aldosterone system in the kidney.
    Nishiyama A, Kobori H.
    Clin Exp Nephrol; 2018 Dec; 22(6):1231-1239. PubMed ID: 29600408
    [Abstract] [Full Text] [Related]

  • 5. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S, García CO, Rodríguez E, Barrios C, Otero S, Mojal S, Pascual J, Soler MJ.
    Nefrologia (Engl Ed); 2018 Dec; 38(2):197-206. PubMed ID: 29102270
    [Abstract] [Full Text] [Related]

  • 6. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
    Slagman MC, Navis G, Laverman GD.
    Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
    [Abstract] [Full Text] [Related]

  • 7. Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease.
    Gupta G, Dahiya R, Singh Y, Mishra A, Verma A, Gothwal SK, Aljabali AAA, Dureja H, Prasher P, Negi P, Kapoor DN, Goyal R, Tambuwala MM, Chellappan DK, Dua K.
    Chem Biol Interact; 2020 Feb 01; 317():108975. PubMed ID: 32032593
    [Abstract] [Full Text] [Related]

  • 8. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR, Rolfe M.
    Clin J Am Soc Nephrol; 2010 Mar 01; 5(3):531-48. PubMed ID: 20150448
    [Abstract] [Full Text] [Related]

  • 9. Role of the renin-angiotensin-aldosterone system in the progression of renal disease: a critical review.
    Ibrahim HN, Rosenberg ME, Hostetter TH.
    Semin Nephrol; 1997 Sep 01; 17(5):431-40. PubMed ID: 9316211
    [Abstract] [Full Text] [Related]

  • 10. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.
    Ahmed AK, Kamath NS, El Kossi M, El Nahas AM.
    Nephrol Dial Transplant; 2010 Dec 01; 25(12):3977-82. PubMed ID: 19820248
    [Abstract] [Full Text] [Related]

  • 11. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states.
    Brewster UC, Setaro JF, Perazella MA.
    Am J Med Sci; 2003 Jul 01; 326(1):15-24. PubMed ID: 12861121
    [Abstract] [Full Text] [Related]

  • 12. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease.
    Komers R, Plotkin H.
    Am J Physiol Regul Integr Comp Physiol; 2016 May 15; 310(10):R877-84. PubMed ID: 27009050
    [Abstract] [Full Text] [Related]

  • 13. Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD.
    Jain AK, Cuerden MS, McLeod I, Hemmelgarn B, Akbari A, Tonelli M, Quinn RR, Oliver MJ, Garg AX.
    Kidney Int; 2012 Jun 15; 81(12):1248-53. PubMed ID: 22437415
    [Abstract] [Full Text] [Related]

  • 14. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L, Kocks MJ, Laverman GD, Navis G.
    Minerva Med; 2004 Oct 15; 95(5):395-409. PubMed ID: 15467515
    [Abstract] [Full Text] [Related]

  • 15. Direct Renin inhibition: promising treatment in renoprotection?
    Loriga G.
    Recent Pat Cardiovasc Drug Discov; 2010 Jun 15; 5(2):113-9. PubMed ID: 20438446
    [Abstract] [Full Text] [Related]

  • 16. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep 15; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 17. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.
    Brewster UC, Perazella MA.
    Am J Med; 2004 Feb 15; 116(4):263-72. PubMed ID: 14969655
    [Abstract] [Full Text] [Related]

  • 18. Interrelationship between renin-angiotensin-aldosterone system and oxidative stress in chronic heart failure patients with or without renal impairment.
    Reina-Couto M, Afonso J, Carvalho J, Morgado L, Ronchi FA, de Oliveira Leite AP, Dias CC, Casarini DE, Bettencourt P, Albino-Teixeira A, Morato M, Sousa T.
    Biomed Pharmacother; 2021 Jan 15; 133():110938. PubMed ID: 33171402
    [Abstract] [Full Text] [Related]

  • 19. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C, Pöss J, Böhm M.
    Drugs; 2010 Jul 09; 70(10):1215-30. PubMed ID: 20568830
    [Abstract] [Full Text] [Related]

  • 20. Update on role of direct renin inhibitor in diabetic kidney disease.
    Dhakarwal P, Agrawal V, Kumar A, Goli KM, Agrawal V.
    Ren Fail; 2014 Jul 09; 36(6):963-9. PubMed ID: 24678880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.